17 / 27
Progression events are relevant…
• Inferior clinical benefit derived from Lenvatinib in rapidly progressive
patients when left to progress (crossed placebo patients)
Schlumberger M, et al. N Engl J Med. 2015;372:621–630.
Open Label
ORR: 52.3%
ORR:
64.8%
Blinded
12,4
10,1
3,6
18,3
0
2
4
6
8 10 12 14 16 18 20
Placebo crossed
(24mg)
Placebo crossed
(all doses)
Placebo
Lenvatinib
PFS (months)